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Objective: Το assess the cost-effectiveness of two treatments (medical treatment and 
  amputation) in patients with diabetic foot syndrome, one of the most disabling diabetic complica-
tions. Diabetes mellitus is a massive health care problem worldwide with a current prevalence 
of 150 millions diabetic cases, estimated to increase to 300 million cases in 2025.
Methods: Integrating medical knowledge and advances into the clinical setting is often difficult 
due to the complexity of the algorithms and protocols. Clinical decision support systems assist 
the clinician in applying new information to patient care through the analysis of patient-specific 
clinical variables. We require strategic decision support to analyze the cost-effectiveness of 
these programs compared to the status quo. We provide a simple partially observable Markov 
model to investigate that issue, and we propose an heuristic algorithm to find the best policy 
of intervention.
Results: This study assesses the potential cost-effectiveness of two alternative treatment 
interventions in patients with diabetic foot syndrome. The implementation of the heuristic 
algorithm solution will assist doctors in clinical decision making, and health care organiza-
tions in evaluating medication choices for effective treatment. Finally, our study reveals that 
treatment programs are highly cost-effective for patients at high risk of diabetic foot ulcers and 
lower extremity amputations.
Keywords: partially observable Markov decision model, diabetic foot syndrome, cost-
  effectiveness method
Introduction
An estimated 24 million Americans suffer from diabetes.1 One of the major risk 
  factors for lower extremity amputation is an antecedent foot ulcer. The symptoms of 
diabetic foot syndrome comprise a loss of protective sensation and, as a consequence, 
a lack of awareness, innervation of small muscles, and diminished fine control of 
pedal circulation. Polyneuropathy peripheral arterial occlusive disease, and   infections, 
lead to diabetic foot syndrome. In most cases, the precipitant of ulceration is an 
accidental trauma which induces breaks of the skin and further complications such 
as ulcers, infections, or gangrene. Small bones may break due to loss of structural 
bone integrity.2 About 15% of all diabetics require foot amputations, and 20%–25% 
of those even require re-amputations. The amputation aims at leaving a wound that 
will heal.3 Prevention programs and therapy at an early stage could diminish the 
number of amputations by as much as 80%–90%.4,5
Researchers have applied several models to investigate the complications of the 
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and determining the severity of infection, as the basis for 
  selecting the appropriate approach to treatment.6,7 Unfor-
tunately, the lack of consensus on wound definitions and 
infection classification systems hampers the comparison 
of published studies. Consensus is developing that the key 
issues in classifying a diabetic foot wound are its depth 
(in   particular, which tissues are involved) and whether the 
wound is complicated by either ischemia or infection.8,9
Some researchers have analyzed the cost-effectiveness of 
treating foot infections in a diabetic cohort10,11 by constructing 
a Markov model with Monte Carlo techniques. These   studies 
combined multiple diabetic complications and analyzed pre-
vention strategies for diabetes. The model predicted the rates 
of microvascular complications and mortality,12   describing 
seven threats to validity for economic evaluations that are 
based on randomized controlled trials. Habacher et al13 
  provide a strong overview of the problems that may be 
encountered with modeling in economic evaluation.
In this paper, we construct and propose a partially observ-
able Markov decision model and assess its implementation in 
the evaluation of diabetes mellitus prevention strategies for 
diabetic foot complications in Greece. Our paper is organized 
in the following sections:
First we present the proposed partially observable Markov 
decision process (POMDP) model, and we describe and discuss 
its underlying data. In the following section, we construct a 
suitable heuristic solution algorithm. The simplicity of the 
proposed algorithm gives the advantage of a supporting tool 
required for the prevention of diabetic foot syndrome (alongside 
clinical examination). In the subsequent section, we present the 
results of the model’s practical implementation in a case study. 
Finally, we discuss our findings and we make some suggestions 
for the practical utilization of the proposed model.
The POMDP model for the 
treatment of diabetic foot 
prevention
In this section we formulate a POMDP model14 in order to 
assess a cost-effectiveness analysis of prevention strategies 
for diabetic foot syndrome. Generally, POMDP models 
have been successfully reviewed for theory and for state-
of-the-art solution algorithms.15–18 To construct a Markov 
model for a particular application, one must first specify the 
Markov states. These health states should not only reflect 
all the relevant states of health associated with diabetes 
and treatment over time, but should also include and take 
into consideration all relevant clinical history. According 
to the international literature on the course of the disease 
  (etiopathology), patients with diabetic foot syndrome pass 
through eight different stages: (Si)19,20
•	 no foot ulcer (S1)
•	 uncomplicated ulcer (S2)
•	 deep foot infection (S3)
•	 foot ulcer and critical ischemia (S4)
•	 primary healing (S5)
•	 minor amputation (S6)
•	 major amputation (S7)
The second step in building a Markov model is to choose 
a cycle length, which must be a constant increment of time. 
So, we used the cycle length of half a year, because studies 
reported wound healing times of about six months for diabetic 
foot ulcers and amputations.2,3,5 A POMDP model is typically 
defined as a six-parameter tuple. The six parameters together 
capture all the required aspects of medical decision making. 
A partially observable decision process is:
POMDP = ,S, A, P, R, Θ, q, β .
•	 S is the set of physical states of a patient with diabetes 
mellitus. As mentioned above, we have seven states.
•	 A(t) ∈ A, decision taken at time t, t = 0, 1, 2, …
In our paper, we suggest that optimal prevention for 
high-risk patients is cost-saving, under the assumption of a 
25% lower incidence of foot ulcers and extremity amputa-
tion compared to baseline prevention scenarios. (Also, we do 
not implement age- and risk group-specific transitions in our 
POMDP model). For simplicity, we consider two alternative 
treatments: medical treatments, and amputation, which are 
coded as 1 and 2 respectively; A = {1, 2}.
•	 Given transition probability matrices:
 
pX tj Xt iDtk ij
k = ( ) =| − ( ) =− ( ) = {} Pr , 11   (2.1)
In preparation for building the POMDP model, we are 
going to specify the transition probabilities with cohort stud-
ies in a central hospital in Athens.
•	 An observation on the system Y (t), and invariant condi-
tional probabilities:
 
rY tx tj dt d i
k
θ θ = ( ) =|( ) =− ( ) = {} Pr ,1  (2.2)
Θ/j may also be assumed to be a continuous random vari-
able, with a known conditional density f (θ/j). In this paper, 
we supposed that in a given time interval (check-up period), 
the physician counts the number of failed tests Y (t) = θ.ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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where λi is the rate of failures tests in state i multiplied by 
the check-up time.17
Family physicians infrequently perform foot examina-
tions in diabetic patients during routine office visits. Careful 
inspection of the diabetic foot on a regular basis is one of the 
easiest, least expensive, and most effective measures for pre-
venting foot complications.7 Appropriate care of the diabetic 
foot requires recognition of the most common risk factors 
for limb loss.21 Many of these risk factors can be identified 
based on specific aspects of the clinical history, and a brief 
and systematic examination of the foot.
Common risk factors for amputation of the diabetic foot 
include peripheral neuropathy, structural foot deformity, 
ulceration, infection, and peripheral vascular disease. It is 
important to recognize that foot ulcers can have a multi-
factorial etiology.22
•	 Peripheral arterial occlusive disease typically involves 
the tibial and peroneal arteries, but spares the dorsalis 
pedis artery.23
•	 The presence of lower extremity ischemia is suggested 
by a combination of clinical signs and symptoms, plus 
abnormal results on noninvasive vascular tests. Signs 
and symptoms may include claudication, and pain 
occurring in the arch or forefoot at rest or during the 
night.21
•	 Noninvasive vascular tests include transcutaneous   oxygen 
measurement, absolute toe systolic pressure, and the 
ankle-brachial index (ABI). The ABI is a noninvasive 
test that can be performed easily in the office using a 
handheld Doppler device. The sensitivity and specific-
ity of noninvasive vascular tests are a matter of some 
controversy.24
•	 Digital symmetric polyneuropathy is perhaps the most 
common complication affecting the lower extremities 
of patients with diabetes mellitus.4
•	 The nylon monofilament test is a simply-performed office 
test to diagnose patients at risk for ulcer formation due to 
peripheral sensory neuropathy. The test is abnormal if the 
patient cannot sense the touch of the monofilament when 
it is pressed against the foot with just enough pressure to 
bend the filament.
•	 Foot deformities, which are common in diabetic patients, 
lead to focal areas of high pressure. When an abnormal 
focus of pressure is coupled with lack of sensation, a foot 
ulcer can develop.23
•	 Also, a diabetic patient with a history of previous 
  ulceration is at increased risk for further ulceration, infec-
tion, and subsequent amputation.
The probabilistic relation between observation process 
Y(t) and core process X(t) is given by the 7 × 7 time-
invariant observation matrix R. We apply the expectation-
maximization (EM) algorithm18 to estimate the above 
observation probabilities. Alternatively, we can apply 
cohort studies.22
•	 Given real values q(i, k), which signify the expected 
incurred immediate costs/rewards in taking action k, 
while being in patient state i.
•	 We have a discount factor β, 0 , β , 1.
In a POMDP model, the state of the patient is not known 
with certainty. The vector of state probabilities π(t) = (π1(t), 
(π2(t), …, (π7(t)) is called the information vector:
πi(t) = Pr {X(t) = i | Y(t), A(t – 1), Y(t – 1), …,
A(1), Y(1), A(0)} 
(2.4)
It is well known that π(t) is a sufficient statistic.25 More 
precisely, π(t) summarizes all of the necessary information 
on the history of the process for choosing an action at time t. 
The probabilities πi(t) in the type (2.4) are updated and reas-
signed to the system states by the decision maker at every 
step t, given the history of the process. However, the update 
of πi(t) is Bayesian, such that the detail of the history is not 
used directly. Specifically,
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where, Pl is the first column of P, and matrix multiplication 
is implied where appropriate. To clarify, the order of things 
in the decision process is the following:
At time t, the state of a patient with diabetes mellitus is 
an unknown state X(t) = i. Based on π(t – 1), the matrices P, 
and the vectors q(⋅, A(t – 1)) a decision is taken: A(t) = k, 
k = 1, 2. Instantaneously, the patient switches to unknown state 
j. According to  pij
k, an immediate average reward or cost   
q(i, k) is gained, and the observation process provides a signal 
Y(t) = θ. The decision maker then updates the state probabili-
ties by (2.5a) or (2.5b). The process repeats itself indefinitely. ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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Focusing on the total discounted reward criterion, we wish 
to optimize the decisions so as to maximize:
 
Eq Xt At
t
t Σ
∞
=
⋅ ( ) ( ) ( )





 0
β ,   (2.6)
for all initial probability vectors π (0). It is assumed that the 
process is initiated with a known probability distribution 
over the state of the patient. The dependence on π(0) has 
been dropped from the notation in (2.6), and 0 , β , 1 is 
a discount factor.
A solution method
The generality of the standard POMDP model14 limits 
  practical application of the framework, due to the com-
putational complexity of associated solution methods. 
However, for many specialized problems, the full-blown 
generality of the POMDP approach and its associated solu-
tion methods is superfluous. In this section, we provide a 
heuristic rule that it is stationary and extremely simple. It runs 
as follows:
step 1
We solve the fully observable problem by Howard’s policy 
iteration,25 and then we value the determination routine. 
We find d*(i) for all 1 # i # 7, where d*(i) stands for 
the Howard’s optimal decision, assuming state i is fully 
observed, d(i) ∈ D. As an output of the algorithm, we get 
the Vi values; the expected total discounted reward   starting 
in state i.
Notably:
 
Vq ip V i
j
n
ij
k
j = ( )+⋅





 =
max,
α
Σ αβ
1
  (3.1)
step 2
For the current state vector π (t), we calculate an approximate 
reward functional   Vt π ( ) ( )
 Vt tq ip V
i i j
n
ij j ππ αβ α
α () () = () ⋅ () +⋅ 


 |= {} == max, , ΣΣ
1
7
1 12   (3.2)
and set  At Vt ( ) == ( ) ( )   απ argmax . The advantage of the 
above algorithm is the fact that it requires only a single run 
of Howard’s routine.
Implementation of the proposed 
model – a case study
For comprehension of the above algorithm, we present the 
implementation results from the treatment of patients with 
diabetic foot syndrome in a middle-sized public hospital in 
Greece, during the year 2008. We have used seven health 
states S = {1, 2, 3, …, 7}, and two treatments A = {1, 2}.
P
1
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.......
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The rewards/costs are derived from the National Statistical 
Service of Greece. The direct costs include drug costs, hospi-
talization costs, monitoring costs, and physician visit costs.
 q (1, 1) = 96�  q(1, 2) = 1330�
 q (2, 1) = 358�  q(2, 2) = 1500�
 q (3, 1) = 370�  q(3, 2) = 2000�
 q (4, 1) = 450�  q(4, 2) = 3000�
 q (5, 1) = 500�  q(5, 2) = 3300�
 q (6, 1) = 600�  q(6, 2) = 8000�
 q (7, 1) = 772�  q(7, 2) = 11000�
The costs for the diabetic foot syndrome, and the 
  model’s effectiveness parameters were taken from various 
studies.20,26–28 We considered a discount factor β = 0.90. When 
estimating transition probabilities, it is important to be mind-
ful of the cohorts or target populations that are to be analyzed, 
as one can have a number of different transition probability 
matrices that are specific for different cohorts, defined by 
demographic or clinical variables. In order to find the final 
information vector, we can use regression models.ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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For example, if the initial information vector for a patient 
with diabetic foot syndrome is π = (0.10, 0.20, 0.10, 0.10, 
0.30, 0.20, 0.00), using Howard’s algorithm, we have:
 V 1 = 296
 V 2 = 454
 V 3 = 1457
 V 4 = 3252
 V 5 = 3496
 V 6 = 5722
 V 7 = 8976
 V π ( ) = {} = max, 3723 3970 3970, and the optimal deci-
sion is amputation:   V
* 52 ( ) = . To clarify, the order of things 
in the decision process according above POMDP model is the 
following. At time t = 0, a patient with diabetic foot syndrome 
has an information vector π(0) = (0.10, 0.20, 0.20, 0.20, 0.30, 
0.00, 0.00). This information vector is a sufficient statistic 
for taking an action.25 In terms of the above model, we take 
amputation after the state “primary healing”. So, the doctor 
has a supporting tool in their decision making.
Discussion
The risk of injury to the diabetic foot is high, and the con-
sequences of injury can be severe. Therefore, prevention 
based upon clinical trials and doctors is undoubtedly the 
best strategy. Decision analytic modeling, undertaken for 
the purpose of economic evaluation of health technologies, 
involves the application of mathematical techniques to syn-
thesize available information about health care processes and 
their implications.10,15,20
In our paper, we provide a simple POMDP model for 
taking a cost-effective decision for the treatment of foot ulcer 
syndrome. Many researchers have proposed similar models 
for the management of diabetic foot ulcer.13,19,29 However, 
in these models, the integration of medical knowledge and 
advances into the clinical setting is often difficult, due to the 
complexity of the algorithms and protocols. So, in our model, 
we propose the incorporation of the required information 
into a Clinical Decision Support System (CDSS), in order 
to analyze the patient-specific clinical variables. In this way, 
we can essentially assist the clinician toward their best medi-
cal decision making. In our proposed model, we also used 
cost-related information, incorporating utility functions, to 
support the cost-effectiveness evaluation of these programs, 
and the strategic management of health care organizations.
So, the main advantage of the proposed model lies in 
the clinician’s capability for full adaptation control, mean-
ing ease of modification of any of the model’s parameters 
incorporated into the CDSS.
Conclusion
This model is significant because it provides an explicit two-way 
bridge between primary clinical data and early and efficient 
medical decision making. Typically, the objective of this deci-
sion model is to obtain a clearer understanding of the relation-
ship between incremental costs and their consequences.
The proposed simple model (incorporated into a CDSS) 
results in health care quality improvement, cost-effective 
clinical decision making, and adaptability and transferability 
through different health care environments (either organiza-
tions or countries). So, the exchange of reliable and timely 
information through various levels of the health care system 
in Greece will facilitate the efficiency and effectiveness of 
the proposed model.
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